cl 387785 has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erlichman, C; Goble, JM; James, CD; Lamont, JD; Mladek, AC; Rao, RD; Sarkaria, JN | 1 |
| Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Imai, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H | 1 |
2 other study(ies) available for cl 387785 and sirolimus
| Article | Year |
|---|---|
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Immunoprecipitation; Models, Biological; Phosphoproteins; Phosphorylation; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Thymidine; TOR Serine-Threonine Kinases | 2005 |
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gene Amplification; Humans; Paclitaxel; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Trastuzumab | 2012 |